Startup Stories

Altera is on a mission to redesign the rules of compatibility by building a universal donor cell platform designed to enable scalable, immune-compatible, off-the-shelf allogeneic therapies for cell and tissue transplantation. Their mission is to remove the barriers of immunogenicity and donor-matching through cell engineering, making cell therapy more scalable, accessible, and impactful across the globe.

Bionuclex is chasing one of the harder problems in biotech: catching multiple cancers early, from a single blood draw, in a way the average person could actually access. Their focus is biomarker discovery for multi-cancer early detection liquid biopsy, the kind of work that only pays off if the science holds up under real scrutiny, and reaches further than a lab.

Immobazyme is a South African precision-fermentation and molecular-design company. They develop and produce high-value proteins, enzymes, and peptides — biomolecules that are difficult, expensive, or impossible to make by conventional means — using a single, modular biotechnology platform built entirely in-house, from gene design through to certified-pure, lyophilised supply.

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

Most cancer patients go through rounds of chemotherapy that fail. Every failed cycle means wasted money, lost time, and needless suffering. Oncolign is a precision oncology startup using tumour organoids and AI to predict the right cancer treatment, first time.

Urobo Biotech is a sustainability-oriented company that is focused on providing innovative solutions to the rise in bioplastic waste. Our technologies enable waste management companies to produce valuable fuels and chemicals from bioplastic waste entering their facilities. Our journey began with a mission: to revolutionise the bioplastics industry and combat plastic pollution.

Coming Soon